Single-stranded RNA-editing oligonucleotides
The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.
1. An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA in a cell, wherein:
a) the AON is complementary to a target RNA region comprising a target adenosine, wherein the AON nucleotide opposite the target adenosine in the double stranded complex formed between the AON and the target RNA is a cytidine or a uridine;
b) the AON comprises one or more nucleotides with one or more sugar modifications, provided that the AON nucleotide opposite the target adenosine does not comprise a 2′-OMe modification;
c) the AON does not comprise a portion that is capable of forming an intramolecular stem-loop structure capable of binding an Adenosine Deaminases Acting on RNA (ADAR) enzyme;
d) the AON does not include a 5′-terminal O6-benzylguanine modification;
e) the AON does not include a 5′-terminal amino modification;
f) the AON is not covalently linked to a SNAP-tag domain; and
g) the AON is shorter than 100 nucleotides; and
wherein formation of the double stranded complex between the AON and the target RNA results in the deamination of the target adenosine by an ADAR enzyme present in the cell.
2. An AON capable of forming a double stranded complex with a target RNA in a cell, wherein:
a) the AON is complementary to a target RNA region comprising a target adenosine, wherein the AON nucleotide opposite the target adenosine in the double stranded complex formed between the AON and the target RNA is a cytidine or a uridine;
b) the AON comprises one or more nucleotides with one or more sugar modifications, provided that the nucleotide opposite the target adenosine does not comprise a 2′-OMe modification;
c) the AON does not comprise a portion that is capable of forming an intramolecular stem-loop structure capable of binding an ADAR enzyme;
d) the AON is shorter than 100 nucleotides; and
(e) the AON is not a 17-mer or a 20-mer; and,
wherein formation of the double stranded complex between the AON and the target RNA results in the deamination of the target adenosine by an ADAR enzyme present in the cell.
3. An AON capable of forming a double stranded complex with a target RNA in a cell, wherein:
a) the AON is complementary to a target RNA region comprising a target adenosine, wherein the AON nucleotide opposite the target adenosine in the double stranded complex formed between the AON and the target RNA is a cytidine or a uridine;
b) the AON comprises one or more nucleotides with one or more sugar modifications, provided that the AON nucleotide opposite the target adenosine does not comprise a 2′-OMe modification;
c) the AON does not comprise a portion that is capable of forming an intramolecular stem-loop structure capable of binding an ADAR enzyme;
d) the AON is shorter than 100 nucleotides; and
e) the AON is longer than 17 nucleotides, or shorter than 14 nucleotides, and
wherein formation of the double stranded complex between the AON and the target RNA results in the deamination of the target adenosine by an ADAR enzyme present in the cell.
4. An AON capable of forming a double stranded complex with a target RNA in a cell, wherein:
a) the AON is complementary to a target RNA region comprising a target adenosine;
b) the AON comprises one or more nucleotides with one or more sugar modifications, provided that the AON nucleotide opposite the target adenosine in the double stranded complex formed between the AON and the target RNA is a cytidine or a uridine that does not comprise a 2′-OMe modification;
c) the AON does not comprise a portion that is capable of forming an intramolecular stem-loop structure that is capable of binding an ADAR enzyme;
d) the AON is shorter than 100 nucleotides; and
(e) the AON comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mismatches, wobbles and/or bulges with the complementary target RNA region, and
wherein formation of the double stranded complex between the AON and the target RNA results in the deamination of the target adenosine by an ADAR enzyme present in the cell.
5. The AON of claim 1 , wherein the cytidine is a deoxycytidine or the uridine is a deoxyuridine.
6. The AON of claim 1 , wherein the nucleotide directly 5′ and/or 3′ from the AON nucleotide opposite the target adenosine in the double stranded complex formed between the AON and the target RNA comprises a ribose with a 2′-OH group, or a deoxyribose with a 2′-H group.
7. The AON of claim 1 , wherein the AON is 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 nucleotides in length.
8. The AON of claim 1 , comprising at least one phosphorothioate linkage.
9. The AON of claim 8 , wherein the 2, 3, 4, 5, or 6 terminal nucleotides of the 5′ terminus and/or 2, 3, 4, 5, or 6 terminal nucleotides of the 3′ terminus of the AON are linked with a phosphorothioate linkage.
10. The AON of claim 9 , wherein the 5 terminal nucleotides of the 5′ terminus and/or the 5 terminal nucleotides of the 3′ terminus of the AON are linked with phosphorothioate linkages.
11. The AON of claim 1 , wherein the AON is longer than 10, 11, 12, 13, 14, 15, 16, 17, or 20 nucleotides.
12. The AON of claim 1 , wherein the AON is shorter than 50 nucleotides or shorter than 60 nucleotides.
13. The AON of claim 1 , wherein the AON is 18 to 70 nucleotides, 18 to 60 nucleotides, or 18 to 50 nucleotides in length.
14. A pharmaceutical composition comprising the AON of claim 1 and a pharmaceutically acceptable carrier.
15. A method of treating or preventing a genetic disorder in a subject in need thereof, the method comprising administering the AON of claim 1 to the subject.
16. A method of deaminating at least one target adenosine present in a target RNA in a cell, the method comprising:
(i) contacting a cell with the AON of claim 1 thereby to permit the AON to enter the cell and an ADAR enzyme comprising a natural dsRNA binding domain to deaminate the target adenosine in the target RNA to an inosine; and
(ii) optionally identifying the presence of the inosine in the targeted RNA.
17. The method of claim 16 , wherein step (ii) comprises:
(a) sequencing the targeted RNA sequence;
(b) assessing the presence of a functional, elongated, full length and/or wild type protein when the target adenosine is located in a UGA or UAG stop codon, which is edited to a UGG codon through the deamination;
(c) assessing the presence of a functional, elongated, full length and/or wild type protein when two target adenosines are located in a UAA stop codon, which is edited to a UGG codon through the deamination of both target adenosines;
(d) assessing whether splicing of the pre-mRNA was altered by the deamination; or
(e) using a functional read-out, wherein the target RNA after the deamination encodes a functional, full length, elongated and/or wild type protein.
18. The AON of claim 1 , wherein the target RNA sequence encodes CFTR, CEP290, alpha1-antitrypsin (A1AT), LRRK2, BDNF, or wherein the target RNA is encoded by the IDUA gene.
19. The method of claim 15 , wherein the genetic disorder is selected from the group consisting of: Cystic fibrosis, Hurler Syndrome, alpha-1-antitrypsin (A1AT) deficiency, Parkinson's disease, Alzheimer's disease, albinism, Amyotrophic lateral sclerosis, Asthma, β-thalassemia, Cadasil syndrome, Charcot-Marie-Tooth disease, Chronic Obstructive Pulmonary Disease (COPD), Distal Spinal Muscular Atrophy (DSMA), Duchenne/Becker muscular dystrophy, Dystrophic Epidermolysis bullosa, Epidermylosis bullosa, Fabry disease, Factor V Leiden associated disorders, Familial Adenomatous, Polyposis, Galactosemia, Gaucher's Disease, Glucose-6-phosphate dehydrogenase, Haemophilia, Hereditary Hematochromatosis, Hunter Syndrome, Huntington's disease, Inflammatory Bowel Disease (IBD), Inherited polyagglutination syndrome, Leber congenital amaurosis, Lesch-Nyhan syndrome, Lynch syndrome, Marfan syndrome, Mucopolysaccharidosis, Muscular Dystrophy, Myotonic dystrophy types I and II, neurofibromatosis, Niemann-Pick disease type A, B and C, NY-esol related cancer, Peutz-Jeghers Syndrome, Phenylketonuria, Pompe's disease, Primary Ciliary Disease, Prothrombin mutation related disorders, such as the Prothrombin G20210A mutation, Pulmonary Hypertension, Retinitis Pigmentosa, Sandhoff Disease, Severe Combined Immune Deficiency Syndrome (SCID), Sickle Cell Anemia, Spinal Muscular Atrophy, Stargardt's Disease, Tay-Sachs Disease, Usher syndrome, X-linked immunodeficiency, and cancer.
20. The AON of claim 1 , wherein the AON comprises one or more mismatches, wobbles and/or bulges with the complementary target RNA region.
21. The AON of claim 1 , comprising at least one modified backbone linkage.
22. The AON of claim 21 , wherein the at least one modified backbone linkage is selected from the group consisting of phosphorothioate, phosphorodithioate, phosphoramidate and combinations thereof.
23. The AON of claim 1 , wherein the nucleotide 5′ and/or 3′ adjacent to the cytidine or the uridine comprise a 2′-O-alkyl group, preferably a 2′-O-methyl group.
24. The AON of claim 1 , wherein the one or more sugar modifications are selected from the group consisting of a 2′-O moiety with a lower alkyl (C1-4), an alkenyl (C2-4), an alkynyl (C2-4), a methoxyethyl (2′-MOE), and combinations thereof.
25. The AON of claim 1 , wherein the one or more sugar modifications are selected from the group consisting of a 2′-O-methyl group, a 2′-methoxyethyl (2′-MOE) group, or a 2′-O-dimethylallyl group, and combinations thereof.
26. The AON of claim 1 , wherein the oligonucleotide is an oligoribonucleotide, a deoxyribonucleotide, or a combination thereof.
27. The AON of claim 1 , wherein the oligonucleotide comprises one or more locked nucleic acids (LNA).
28. The AON of claim 1 , wherein the one or more sugar modifications is a 2′-fluoro group, a 2′-O-lower alkyl (C1-4)-group, a 2′-O-alkenyl (C2-4), a 2′-O-alkynyl (C2-4), a 2′-O-methoxyethyl group, a 2′-NH 2 group, or a 2′-O-3,3′dimethylallyl group.
29. The AON of claim 1 , wherein the cell is a eukaryotic cell.
30. The AON of claim 29 , wherein the eukaryotic cell is a mammalian cell or a human cell.
31. The AON of claim 1 , wherein the cell is a skin cell, a lung cell, a heart cell, a kidney cell, a liver cell, a pancreas cell, a gut muscle cell, a gland cell, an eye cell, a brain cell, or a blood cell.
32. The AON of claim 1 , wherein the cell is a stem cell.
33. The AON of claim 32 , wherein the stem cell is an embryonic stem cell, a pluripotent stem cell, a totipotent stem cell, or an induced pluripotent stem cell.
34. An AON capable of forming a double stranded complex with a target RNA in a cell, wherein:
(a) the target RNA encodes CFTR, CEP290, alpha1-antitrypsin (A1AT), LRRK2, or BDNF, or the target RNA is encoded by the IDUA gene;
(b) the AON is complementary to a target RNA region comprising a target adenosine;
(c) the AON comprises one or more nucleotides with one or more sugar modifications;
(d) the AON does not comprise a portion that is capable of forming an intramolecular stem-loop structure that is capable of binding an ADAR enzyme;
(e) the AON is shorter than 100 nucleotides;
(f) the AON optionally comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mismatches, wobbles and/or bulges with the complementary target RNA region, and,
wherein formation of the double stranded complex between the AON and the target RNA results in the deamination of the target adenosine by an ADAR enzyme present in the cell.
35. The AON of claim 34 , wherein
(i) the target adenosine in the target RNA encoding CFTR is adenosine 1784 of a G1784A CFTR mutant;
(ii) the target adenosine in the target RNA encoding CEP290 is adenosine 1655 of a c.2991+G1655A CEP290 mutant;
(iii) the target adenosine in the target RNA encoding alpha1-antitrypsin (A1AT) is adenosine 9989 of a G9989A A1AT mutant;
(iv) the target adenosine in the target RNA encoding alpha1-antitrypsin (A1AT) is adenosine 1096 of a G9989A A1AT mutant;
(v) the target adenosine in the target RNA encoding LRRK2 is adenosine 6055 of a G6055A LRRK2 mutant;
(vi) the target adenosine in the target RNA encoding BDNF is an adenosine in the methionine 66 codon of a Val66Met mutant; or,
(vii) the target adenosine in the target RNA encoded by the IDUA gene is an adenosine in alanine 1205 codon of a c.1205C>A (W402X) mutant.
36. The AON of claim 34 , wherein the AON targeting the target RNA encoded by the IDUA gene has the plain sequence corresponding to ADAR65 (SEQ ID NO:13), ADAR65-2 (SEQ ID NO:24), ADAR65-2x (SEQ ID NO:25), ADAR66 (SEQ ID NO:14), ADAR67 (SEQ ID NO:15), ADAR91 (SEQ ID NO:26), ADAR93 (SEQ ID NO:27), ADAR93-2 (SEQ ID NO:28), ADAR93-3 (SEQ ID NO:29), ADAR93-4 (SEQ ID NO:30), or ADAR93-5 (SEQ ID NO:31).
37. The AON of claim 34 , wherein the AON targeting the target RNA encoded by the IDUA gene has the modified sequence corresponding to ADAR65 (SEQ ID NO:13), ADAR65-2 (SEQ ID NO:24), ADAR65-2x (SEQ ID NO:25), ADAR66 (SEQ ID NO:14), ADAR67 (SEQ ID NO:15), ADAR91 (SEQ ID NO:26), ADAR93 (SEQ ID NO:27), ADAR93-2 (SEQ ID NO:28), ADAR93-3 (SEQ ID NO:29), ADAR93-4 (SEQ ID NO:30), or ADAR93-5 (SEQ ID NO:31).
38. The AON of claim 34 , wherein the AON targeting the target RNA encoding BDNF has the plain sequence corresponding to BDNF AON1 (SEQ ID NO:36), BDNF AON2 (SEQ ID NO:37), or BDNF AON3 (SEQ ID NO:38).
39. The AON of claim 34 , wherein the AON targeting the target RNA encoding BDNF has the modified sequence corresponding to BDNF AON1 (SEQ ID NO:36), BDNF AON2 (SEQ ID NO:37), or BDNF AON3 (SEQ ID NO:38).
40. The AON of claim 34 , wherein the AON is shorter than 60 nucleotides.
41. The AON of claim 34 , wherein the length of the AON is 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.